PMID- 19125962
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20171116
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 10
IP  - 1
DP  - 2009 Jan
TI  - Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and 
      correlations with predictors of cardiovascular disease.
PG  - 28-34
LID - 10.1111/j.1468-1293.2008.00649.x [doi]
AB  - OBJECTIVE: We evaluated hyperhomocysteinaemia (HHcy) in a cohort of HIV-infected 
      patients in order to assess its relation to cardiovascular risk (CVR) and 
      identify determinants of HHcy variability. METHODS: Cross-sectional observational 
      study. HIV-infected patients on stable highly active antiretroviral therapy (ART) 
      were evaluated for the presence of the metabolic syndrome, lipodystrophy and 
      traditional CVR factors. Plasma homocysteine levels were measured using 
      high-performance liquid chromatography. RESULTS: Five hundred and sixty-seven 
      patients (38% female) with a median age of 44 years were included in the study. 
      Homocysteine (Hcy) was significantly higher in patients with the metabolic 
      syndrome and lipodystrophy. No significant association was found between Hcy 
      levels and the use of ART. However, Hcy was associated with higher blood 
      pressure, waist circumference and waist-to-hip ratio, total lean body mass, 
      visceral adipose tissue (VAT), VAT/total adipose tissue, homeostasis model 
      assessment of insulin resistance (HOMA-IR), triglycerides, high-density 
      lipoprotein cholesterol, apolipoprotein A1, B, and creatinine. All 10-year CVR 
      assessment scores were significantly associated with Hcy. In a multivariate 
      regression model, systolic blood pressure, vitamin supplementation and HOMA-IR 
      were significantly and independently related to Hcy. CONCLUSIONS: Hcy is elevated 
      in HIV-infected patients and is significantly associated with increased CVR. 
      Measurement of Hcy might be useful in identifying particularly high-risk 
      populations at whom therapeutic interventions could be targeted.
FAU - Guaraldi, G
AU  - Guaraldi G
AD  - Department of Medicine and Medical Specialties, Infectious Diseases Clinic, 
      Emilia School of Medicine, University of Modena and Reggio Emilia, Modena, Italy. 
      g.guaraldi@unimo.it
FAU - Ventura, P
AU  - Ventura P
FAU - Garlassi, E
AU  - Garlassi E
FAU - Orlando, G
AU  - Orlando G
FAU - Squillace, N
AU  - Squillace N
FAU - Nardini, G
AU  - Nardini G
FAU - Stentarelli, C
AU  - Stentarelli C
FAU - Zona, S
AU  - Zona S
FAU - Marchini, S
AU  - Marchini S
FAU - Moriondo, V
AU  - Moriondo V
FAU - Tebas, P
AU  - Tebas P
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Adult
MH  - Anthropometry
MH  - Antiretroviral Therapy, Highly Active
MH  - Biomarkers
MH  - Cardiovascular Diseases/*etiology/metabolism
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/*complications/metabolism
MH  - *HIV-1
MH  - HIV-Associated Lipodystrophy Syndrome/*complications/metabolism
MH  - Homocysteine/blood
MH  - Humans
MH  - Hyperhomocysteinemia/*complications/metabolism
MH  - Male
MH  - Metabolic Syndrome/*complications/metabolism
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Assessment
EDAT- 2009/01/08 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/01/08 09:00
PHST- 2009/01/08 09:00 [entrez]
PHST- 2009/01/08 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - HIV649 [pii]
AID - 10.1111/j.1468-1293.2008.00649.x [doi]
PST - ppublish
SO  - HIV Med. 2009 Jan;10(1):28-34. doi: 10.1111/j.1468-1293.2008.00649.x.